NewsRoom Articles - Page 2 of 54 - PsychedelicNewsWire (PNW)

FridayApr 09, 2021 2:44 pm

Integration Proves Its Importance When Treating Mental Conditions Using Psychedelics

For a big chunk of his adult life, Nick Watchorn suffered from serious PTSD, before seeking psychedelic treatments, which helped him manage his condition. Watchorn revealed that the psychoactive sessions he attended and the work that he did on himself afterwards, through a process he refers to as integration, saved his life. He states that before he received the therapeutic treatments (MDMA-assisted therapy), he thought he was too far gone. Watchorn, now 54, had been plagued for more than two decades by the memories of a mass shooting that he’d experienced as a young police officer. The shooting, which occurred…

ThursdayApr 08, 2021 2:25 pm

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Commercialization Team Set to Launch Rapid POC COVID Test Solution

Bioscience technology accelerator XPhyto Therapeutics Corp. is working with development partner 3a-diagnostics GmbH to roll out its pandemic-related virus diagnostic tool for the European market planned in April The test solution, dubbed “Covid-ID Lab,” received European regulatory approval last month XPhyto’s product is designed to be portable and rapid in its response time to help decrease testing operation costs and increase convenience of use News reports about the COVID-19 pandemic reflect a growing optimism that vaccine, mask and distancing protocols may be helping to drive down infection rates, although the reports note the virus continues to have a deadly effect…

ThursdayApr 08, 2021 11:15 am

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) at Front of Line for Cutting-Edge Vitalis Extraction Technology

Annual growth of 17% is forecast for cannabis extraction market to reach $28.5 billion by 2027 Pure Extracts Technologies is already operating leading extraction systems from Vitalis and will soon become one of the first companies to have Vitalis’ new Cosolvent Injection System (“CIS”) The CIS delivers dramatically faster throughput capacities, even higher-quality cannabis extracts, optimal ethanol cosolvent flow rates and low ethanol usage Analysts are aligned on the future of the cannabis extraction market, with expectations for years of double-digit compound annual growth rates. The market experts at Grand View Research see 16.6% CAGR for the market to reach…

ThursdayApr 08, 2021 10:00 am

Three Studies Investigate the Role of Psychedelics in Treating OCD

Recent psychedelic research has led to significant breakthroughs in the field. The substances have been found to be useful in treating various mental health conditions such as depression as well as addiction. Additionally, new research has found that psilocybin, which is the active ingredient in magic mushrooms, is useful in treating obsessive-compulsive disorder (“OCD”). There are three studies looking into the use of psilocybin to decrease the symptoms of obsessive-compulsive disorder. While each study is using different treatment techniques, the evidence they’ve uncovered may be crucial in helping researchers understand the therapeutic mechanism behind psychedelic drugs. Generally, OCD is characterized…

WednesdayApr 07, 2021 12:30 pm

Psilocybin Has Potential to Curb the Global Obesity Crisis

Psychedelics substances such as psilocybin have been found to be helpful in treating obesity and weight issues. Healthline found that more than one-third of adults in America are obese. Nearly 17% of children, ages 2 to 19, are also considered obese. Additionally, obesity has been linked to more than 60 chronic illnesses, including cancer, stroke, heart disease and type 2 diabetes. Worldwide, obesity has gotten worse, and if a substance such as psilocybin can help fight obesity and weight issues, we may be looking at a potential game changer. Various psychedelic companies have been studying psychedelics, looking for ways to…

TuesdayApr 06, 2021 1:23 pm

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Completes Pre-Clinical Studies, Progresses Two Drug Candidates

Cybin has completed more than 20 pre-clinical studies in record time. Company is advancing two new therapeutic candidates with enhanced, improved properties. Drug candidates are designed to treat serious psychiatric conditions with high unmet medical needs. Cybin (NEO: CYBN) (OTCQB: CLXPF), a leading biotech company focused on progressing psychedelic therapeutics, has completed key research studies both in vitro and in vivo. The company recently announced that it had completed its 20th pre-clinical study and had progressed two psychedelic investigational new drug candidates: CYB003 and CYB004 (https://ibn.fm/jDvFz). The studies were completed in record time, the company reported, in part because of close collaboration with…

TuesdayApr 06, 2021 12:30 pm

Researchers Find Traits That May Help Identify Study Subjects Who Could Benefit from Psychedelic Therapy

The number of studies that focus on psychedelics and the benefits they possess as therapies for various mental health conditions has increased tremendously in the last few years. Psychedelics such as LSD and psilocybin mushrooms have shown their potential as possible therapies for conditions such as depression and PTSD, and while many hope that these drugs will be approved as therapies soon, there are those who are concerned about the effects these drugs may have on patients who participate in clinical trials for their study. New research has identified traits that have been linked to negative and positive experiences on…

MondayApr 05, 2021 2:44 pm

Australian Researchers to Conduct Study on Managing Meth Addiction Using Psilocybin

Researchers from Sydney, Australia, are planning a clinical trial with the objective to discover whether administering psychedelics, specifically psilocybin, to individuals who use methamphetamines, commonly known as “meth,” could help manage their addiction. Psilocybin is the active psychedelic ingredient found in magic mushrooms. The scientists from St. Vincent’s Hospital, Darlinghurst, will administer psychedelic therapy to patients who are dependent on ice, or meth. A St. Vincent specialist in toxicology, clinical pharmacology and addiction medicine, lead researcher Dr. Jonathan Brett stated that he was extremely aware of the pressures to carry out the trial in the strictest scientific and ethical boundaries.…

ThursdayApr 01, 2021 12:17 pm

Lumenate App Takes Users on a Trip, Sans Psychedelics

Psychedelics went mainstream a few years ago, and with research on these substances and their therapeutic benefits still ongoing, various jurisdictions across the United States have been considering whether to legalize or decriminalize magic mushrooms as well as other entheogenic fungi and plants. Additionally, more companies are developing psychedelic compounds as consumer products or medications in a bid to profit from the incoming regulatory environment. One of these is Lumenate, a company founded by Jay Conlon and Tom Galea. The two inventors have devised a way to induce a semi-psychedelic state using a device that can be found everywhere in…

WednesdayMar 31, 2021 2:15 pm

Australian Government to Give $15M Grant for Psychedelics Research Focusing on Mental Health

The federal government of Australia will be granting $15 million to clinical studies that look into the use of psychedelics substances such as ecstasy and psilocybin mushrooms for the treatment of mental health conditions. This grant is an important breakthrough in the fight against mental illnesses, especially with nearly half of all adults in Australia set to face mental health issues in the course of their lives. Black Dog Institute, a medical research institute that is dedicated to studying mental health, found that one in five adults experience symptoms of mental conditions in any given year. In the country, that’s…

News and publishing service for psychedelic related companies

Contact us: 415.949.5050